Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability
Johns Hopkins University
Summary
The main purpose of the current studies is to evaluate the safety and tolerability of psilocybin in patients with chronic stroke.
Description
Stroke is the leading cause of death and adult disability worldwide, and every year more than 795,000 people in the United States have a stroke. According to the National Stroke Association, only 10 percent of people who have a stroke recover completely, while 50 percent experience moderate to severe long-term disability, including significant impairment in language, cognition, motor, and sensory skills, which require special care or long-term care in a nursing home or other facility. Therefore, in the United States alone, nearly 400,000 people per year will suffer the lasting debilitating con…
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Over age 18 years, inclusive. * Ischemic or hemorrhagic stroke confirmed by CT or MRI, at least 12 months prior to admission date * Ability to give informed consent and understand the tasks involved. * Agree that, for the study duration, will refrain from: (1) No new prescription medications during the time of the study without approval of the study team, (2) taking any herbal supplement (except with prior approval of the research team), (3) taking any nonprescription medications with the exception of: 1. non-steroidal anti-inflammatory drugs. 2. acetaminophen. 3. vitami…
Interventions
- DrugPsilocybin (Usona Institute)
Participants will receive psilocybin to test its safety. Secondary outcomes will assess recovery from post-stroke deficits.
Location
- Johns HopkinsBaltimore, Maryland